Table 1.
Characteristics of randomized trials that assessed the use of low-dose aspirin to prevent preeclampsia in the early stages of pregnancy
| Authors, year | N | Inclusion criteria | Aspirin | Control group | Onset (weeks) | Outcomes |
|---|---|---|---|---|---|---|
| Ayala et al. [42] (2013) | 350 | History, risk factor | 100 mg | Placebo | 13 | PE, preterm delivery, stillbirth, IUGR |
| Beaufils et al. [33] (1985) | 102 | History, risk factors | 150 mg | No treatment | 14 | PE, gestational HTN, severe PE, birth weight, IUGR |
| CLASP [35] (1994) | 9,309 | History, risk factors | 60 mg | Placebo | 12–32 | PE, IUGR, stillbirth |
| Caritis et al. [36] (1998) | 523 | High risk | 60 mg | Placebo | ≤16 | PE, preterm birth, SGA, abruptio placenta |
| Ebrashy et al. [72] (2005) | 139 | Abnormal uterine artery Doppler plus history, risk factors | 75 mg | No treatment | 14–16 | Preterm PE, PE, IUGR, preterm delivery |
| Goffinet [73] (1996) | 970 | History, risk factors | 60 mg | Placebo | 12–32 | PE, preterm delivery, IUGR, birthweight, stillbirth |
| Golding et al. [74] (1998) | 6,049 | Nulliparity | 60 mg | Placebo | 12–32 | Gestational HTN, PE, eclampsia, birthweight, preterm birth |
| Hermida et al. [75] (1999) | 350 | History, risk factors | 100 mg | Placebo | 12–16 | IUGR, preterm birth, abruptio placenta |
| Michael and Walters [76] (1992) | 110 | Chronic HTN | 100 mg | Placebo | 16 | PE, gestational HTN |
| Morris et al. [77] (1996) | 102 | Nulliparous women with abnormal uteroplacental resistance at 18 weeks of gestation | 100 mg | Placebo | 17–19 | Fetal growth restriction, PE, preterm birth, perinatal death |
| Rolnik et al. [63] (2017) | 1,620 | A high risk for preterm PE according to the screening algorithm | 150 mg | Placebo | 11–14 | Preterm PE, PE, gestational HTN, SGA, stillbirth, abruption, preterm birth, poor fetal growth |
| Villa et al. [78] (2013) | 121 | Abnormal uterine artery Doppler plus history | 100 mg | Placebo | 12–14 | PE, gestational HTN, birthweight, SGA |
| Zhao et al. [79] (2012) | 237 | Hypertension, history, risk factors | 75 mg | Placebo | 13–16 | PE, preterm birth, SGA, stillbirth, delivery mode, gestational age at delivery |
PE, preeclampsia; IUGR, intrauterine growth restriction; HTN, hypertension; CLASP, collaborative low-dose aspirin study in pregnancy; SGA, small-for-gestational-age.